Essential role of cdc42 in Ras-Induced transformation revealed by gene targeting

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Stengel, Kristy R ^a   Zheng, Yi ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN CDC42; PROTEIN KINASE B; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CDC42 GENE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; EMBRYO; GENE; GENE DELETION; GENE FUNCTION; GENE LOSS; GENE TARGETING; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; CDC42 GTP-BINDING PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; GENE TARGETING; GENES, RAS; HUMANS; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862490151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037317     Document Type: Article

References (41)

1. Schubbert S, Shannon K, Bollag G, (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
2. Cox AD, Der CJ, (2010) Ras history: The saga continues. Small Gtpases 1: 2-27.
3. Trahey M, McCormick F, (1987) A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238: 542-545.
4. Saxena N, Lahiri SS, Hambarde S, Tripathi RP, (2008) RAS: target for cancer therapy. Cancer Invest 26: 948-955.
5. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
6. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112.
7. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834.
8. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
9. McCormick F, (2011) Cancer therapy based on oncogene addiction. J Surg Oncol 103: 464-467.
10. Cheng CM, Li H, Gasman S, Huang J, Schiff R, et al. (2011) Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol Cell Biol 31: 983-997.
11. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, et al. (2009) FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 35: 11-25.
12. Stengel K, Zheng Y, (2011) Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal 23: 1415-1423.
13. Zheng Y, Bagrodia S, Cerione RA, (1994) Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J Biol Chem 269: 18727-18730.
14. Beeser A, Jaffer ZM, Hofmann C, Chernoff J, (2005) Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 280: 36609-36615.
15. King AJ, Sun H, Diaz B, Barnard D, Miao W, et al. (1998) The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396: 180-183.
16. Li W, Chong H, Guan KL, (2001) Function of the Rho family GTPases in Ras-stimulated Raf activation. J Biol Chem 276: 34728-34737.
17. Qiu RG, Abo A, McCormick F, Symons M, (1997) Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 17: 3449-3458.
18. Feig LA, (1999) Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. Nat Cell Biol 1: E25-27.
19. Yang L, Wang L, Zheng Y, (2006) Gene targeting of Cdc42 and Cdc42GAP affirms the critical involvement of Cdc42 in filopodia induction, directed migration, and proliferation in primary mouse embryonic fibroblasts. Mol Biol Cell 17: 4675-4685.
20. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR, (2009) Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J Cell Sci 122: 3037-3049.
21. Joberty G, Petersen C, Gao L, Macara IG, (2000) The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2: 531-539.
22. Etienne-Manneville S, Hall A, (2001) Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 106: 489-498.
23. Etienne-Manneville S, Hall A, (2003) Cdc42 regulates GSK-3beta and adenomatous polyposis coli to control cell polarity. Nature 421: 753-756.
24. Olson MF, Ashworth A, Hall A, (1995) An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269: 1270-1272.
25. Yang L, Wang L, Geiger H, Cancelas JA, Mo J, et al. (2007) Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci U S A 104: 5091-5096.
26. Chen L, Liao G, Yang L, Campbell K, Nakafuku M, et al. (2006) Cdc42 deficiency causes Sonic hedgehog-independent holoprosencephaly. Proc Natl Acad Sci U S A 103: 16520-16525.
27. Metz T, Harris AW, Adams JM, (1995) Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell 82: 29-36.
28. Wang R, Brattain MG, (2006) AKT can be activated in the nucleus. Cell Signal 18: 1722-1731.
29. Lin R, Bagrodia S, Cerione R, Manor D, (1997) A novel Cdc42Hs mutant induces cellular transformation. Curr Biol 7: 794-797.
30. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B, (2002) Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87: 635-644.
31. Fritz G, Just I, Kaina B, (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687.
32. Gomez Del Pulgar T, Valdes-Mora F, Bandres E, Perez-Palacios R, Espina C, et al, (2008) Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol 33: 185-193.
33. Tucci MG, Lucarini G, Brancorsini D, Zizzi A, Pugnaloni A, et al. (2007) Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br J Dermatol 157: 1212-1216.
34. Appledorn DM, Dao KH, O'Reilly S, Maher VM, McCormick JJ, (2010) Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts. BMC Cancer 10: 13.
35. Minden A, Lin A, Claret FX, Abo A, Karin M, (1995) Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157.
36. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, et al. (2002) Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 4: 343-350.
37. Fehrenbacher N, Bar-Sagi D, Philips M, (2009) Ras/MAPK signaling from endomembranes. Mol Oncol 3: 297-307.
38. Cerione RA, (2004) Cdc42: new roads to travel. Trends Cell Biol 14: 127-132.
39. Wu WJ, Tu S, Cerione RA, (2003) Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114: 715-725.
40. Melendez J, Grogg M, Zheng Y, (2011) Signaling role of Cdc42 in regulating mammalian physiology. J Biol Chem 286: 2375-2381.
41. Bosco EE, Ni W, Wang L, Guo F, Johnson JF, et al. (2010) Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. Blood 115: 3320-3328.